推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

… MODEL OF HYPERCHOLESTEROLEMIA, UREMIA AND ATHEROSCLEROSISCORRECTION OF HYPERPHOSPHATEMIA SUPPRESSES CARDIAC REMODELING …

K McCabe, N Shobeiri, D Beseau… - NDT …, 2011 - ndtplus.oxfordjournals.org
METHODS: Sprague Dawley rats were fed a diet containing either 0.25% adenine (CKD) or
0% adenine (control), both diets containing high phosphate (1%) and low vitamin K (0.2
mg/kg). Warfarin (0.1 mg/kg body weight/day) was administered in the drinking water of ...

Sirtuin 1 Retards Hyperphosphatemia-Induced Calcification of Vascular Smooth Muscle Cells

A Takemura, K Iijima, H Ota, BK Son… - … and Vascular Biology, 2011 - Am Heart Assoc
Objective—Arterial calcification is associated with cardiovascular disease as a complication
of advanced atherosclerosis. Aged vascular cells manifest some morphological features of a
senescent phenotype. Recent studies have demonstrated that mammalian sirtuin 1 ...
Related articles - All 3 versions

68 Lanthanum Carbonate (LC) vs Sevelamer for Treating Hyperphosphatemia in CKD

JB Copley, R Pratt, P Martin, R Wilson… - American Journal of …, 2011 - urologyaccess.org
« PreviousNext »American Journal of Kidney Diseases Volume 57, Issue 4 , Page B33, April
2011. 68 Lanthanum Carbonate (LC) vs Sevelamer for Treating Hyperphosphatemia in CKD.
J. Brian Copley*: Affiliations. Shire Pharmaceuticals, Wayne, PA, USA. ,; Raymond Pratt: ...
Cached - All 5 versions

Low Protein Diet Prevents Hypoproteinemia, Hypoalbuminemia and Hyperphosphatemia as Well as Secondary Hyperparathyroidism in Diabetic End Stage Renal …

K Arita, E Kihara, K Takahashi… - Advances in Chronic …, 2011 - ackdjournal.org
... EMAIL TO A COLLEAGUE. RIGHTS/PERMISSIONS. NEED REPRINTS? BOOKMARK ARTICLE.
Low Protein Diet Prevents Hypoproteinemia, Hypoalbuminemia and Hyperphosphatemia as
Well as Secondary Hyperparathyroidism in Diabetic End Stage Renal Disease. ...
Cached - All 2 versions

Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

KJ Martin… - Clinical Journal of the American Society …, 2011 - Am Soc Nephrol
Phosphate retention and, later, hyperphosphatemia are key contributors to chronic kidney disease
(CKD)–mineral and bone disorder (MBD). Phosphate homeostatic mechanisms maintain normal
phosphorus levels until late-stage CKD, because of early increases in parathyroid ...
Cited by 1 - Related articles - All 3 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451